T2 Biosystems (NSDQ:TTOO) and Canon U.S. Life Sciences are teaming up to develop a diagnostic test panel for the rapid detection of Lyme disease.
T2 Biosystems Inc.
T2 Biosystems jumps on FDA nod for sepsis tests
IPO or bust for emerging medtechs
FTC wants more data on MDT-COV deal | Medtech Wall Street news for the week of August 11, 2014
T2 Biosystems IPO raises $57M for MRI-based diagnostics
Massachusetts-based T2 Biosystems (NSDQ:TTOO) fell below target with its initial public offering today, raising $57 million in support of its MRI-based diagnostic systems.
T2 Biosystems boosts IPO cap to $78.2M
Massachusetts-based T2 Biosystems raised its hopes for its upcoming initial public offering, raising its maximum aggregate take to $78.2 million if shares sell at $17 apiece.
T2 Biosystems prepares to go public in an offering that could garner $69 million | Medtech Wall Street news for the week of July 7, 2014
T2 Biosystems prepares $69M IPO for MRI-based diagnostics
Diagnostics-maker T2 Biosystems is preparing to go public in an offering that could garner as much as $69 million, according to SEC filings.